Myovant Sciences Ltd  

(Public, NYSE:MYOV)   Watch this stock  
Find more results for MYOV
+0.34 (2.33%)
Feb 20 - Close
NYSE real-time data - Disclaimer
Currency in USD
Range 14.61 - 15.11
52 week 9.92 - 18.85
Open 14.85
Vol / Avg. 0.00/24,111.00
Mkt cap 911.18M
P/E     -
Div/yield     -
EPS -1.96
Shares 60.99M
Beta     -
Inst. own 21%

Key stats and ratios

Q4 (Dec '17) 2017
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -122.26% -90.07%
Return on average equity -166.80% -100.20%
Employees 71 -
CDP Score - -


20-22 Bedford Row
United Kingdom - Map
+44-1824-8101 (Phone)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Myovant Sciences Ltd. is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for women’s health diseases and other endocrine-related disorders. Its main product candidate is Relugolix. Relugolix is an oral, once-daily, small molecule that acts as a gonadotropin-releasing hormone (GnRH) receptor antagonist that binds to and inhibits receptors in the anterior pituitary gland. Inhibition of GnRH receptors decreases the release of the gonadotropins, luteinizing hormone, or LH, and follicle-stimulating hormone, or FSH, thereby decreasing the down-stream production of estrogen and progesterone by the ovaries in women and testosterone by the testes in men. It is advancing relugolix for the treatment of heavy menstrual bleeding associated with uterine fibroids, endometriosis-associated pain and prostate cancer. It intends to develop its second product candidate, RVT-602, for the treatment of female infertility as part of assisted reproduction.

Officers and directors

Lynn Seely M.D. Principal Executive Officer, Director
Age: 58
Bio & Compensation  - Reuters
Frank L. Karbe Principal Financial, Accounting Officer
Age: 49
Bio & Compensation  - Reuters
Marianne L. Romeo Head, Global Transactions & Risk Management
Age: 49
Bio & Compensation  - Reuters
Terrie Curran Director
Age: 48
Bio & Compensation  - Reuters
Keith S. Manchester M.D. Director
Age: 48
Bio & Compensation  - Reuters
Vivek Ramaswamy Director
Age: 31
Bio & Compensation  - Reuters
Mark Altmeyer Independent Director
Age: 56
Bio & Compensation  - Reuters
Wayne S. DeVeydt Independent Director
Age: 47
Bio & Compensation  - Reuters